Q1 27 EPS
$N/A
Q1 27 Revenue
N/A
vs S&P Since Q1 27
+3.1%
BEATING MARKET
MCK +2.5% vs S&P -0.6%
Market Reaction
Did MCK Beat Earnings? Q1 2027 Results
McKesson delivered a mixed fiscal fourth-quarter report for Q4 2026, posting adjusted EPS of $11.69 that edged past the $11.57 consensus estimate by 1.05%, while revenue of $96.30 billion fell short of the $101.38 billion Wall Street expected, a 5.02… Read more McKesson delivered a mixed fiscal fourth-quarter report for Q4 2026, posting adjusted EPS of $11.69 that edged past the $11.57 consensus estimate by 1.05%, while revenue of $96.30 billion fell short of the $101.38 billion Wall Street expected, a 5.02% miss, despite growing 6.0% year over year. The headline earnings strength was anchored by the Oncology and Multispecialty segment, where revenue surged 35% to $12.71 billion and adjusted operating profit climbed 53% to $385.00 million, fueled by specialty distribution growth and contributions from recent acquisitions including PRISM Vision and Core Ventures. North American Pharmaceutical, which accounts for the bulk of McKesson's revenue at $79.12 billion in the quarter, also contributed with 11% adjusted operating profit growth. The results come as pharmaceutical distribution peers broadly navigate pricing headwinds across the industry. Looking ahead, McKesson guided fiscal 2027 adjusted EPS to a range of $43.80 to $44.60, representing 12% to 14% growth, while reaffirming long-term annual EPS expansion targets of 13% to 16%.
Key Takeaways
- • Growth in distribution of oncology and multispecialty products, including contributions from acquisitions
- • Increased prescription transaction volumes, including higher volumes from specialty products
- • Lower share count due to robust share repurchase program
- • Lower tax rate in the fourth quarter
- • Higher demand for access solutions in Prescription Technology Solutions
- • Growth in specialty product distribution to health systems
MCK Forward Guidance & Outlook
McKesson established fiscal 2027 Adjusted Earnings per Diluted Share guidance of $43.80 to $44.60, representing 12% to 14% forecasted growth compared to fiscal 2026. The company reaffirmed long-term Adjusted Earnings per Diluted Share growth targets of 13% to 16%, as well as long-term Adjusted Segment Operating Profit growth targets: North American Pharmaceutical 5% to 8%, Oncology & Multispecialty 13% to 16%, and Prescription Technology Solutions 10% to 13%. The company does not provide forward-looking guidance on a GAAP basis.
MCK YoY Financials
Q1 2027 vs Q1 2026, source: SEC Filings
MCK Revenue by Segment
With YoY comparisons, source: SEC Filings
“McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise.”
— Brian Tyler, Q1 2027 Earnings Press Release
MCK Earnings Trends
MCK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
MCK EPS Trend
Earnings per share: estimate vs actual
MCK Revenue Trend
Quarterly revenue: estimate vs actual
MCK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 27 | — | — | — | — | — |
| Q4 26 BEAT FY | $11.57 | $11.69 | +1.04% | $96.30B | -5.02% |
| FY Full Year | $39.01 | $39.11 | +0.25% | $403.43B | -1.24% |
| Q3 26 BEAT | $9.27 | $9.34 | +0.76% | $106.16B | +0.23% |
| Q2 26 BEAT | $9.05 | $9.86 | +8.95% | $103.15B | -0.93% |
| Q1 26 BEAT | $8.15 | $8.26 | +1.35% | $97.83B | +1.55% |